RSV vaccine highly effective in preventing hospitalisation
Source: UKHSA, 31 July 2025
A new UK Health Security Agency study – Effectiveness of RSV Vaccine Against RSV Associated Hospitalisation Among Adults Aged 75 to 79 years in England – in partnership with Nottingham University Hospitals and other NHS trusts, shows the RSV vaccine provided strong protection for older people, around 82% effective in preventing hospital admissions with RSV infection.
The study also found that the vaccine is highly effective in preventing hospitalisation for older people with a chronic respiratory condition and those living with immunosuppression.
Two new Respiratory Syncytial Virus (RSV) vaccination programmes were introduced to the NHS Vaccination Schedule in September last year; an older adults programme and a maternal programme.
The programme for older adults offers the vaccine to those turning 75, as well as a one-off catch up campaign for all adults aged 75 to79 years.
The maternal vaccination programme is offered to women from 28 weeks of pregnancy to protect newborns, who are at higher risk of severe illness from RSV.
A separate new study – Vaccination in Pregnancy and RSV Hospitalisation in Infants in the UK, led by NHS paediatricians, published in the Lancet Child and Adolescent Health – found that the maternal RSV vaccine was 72% effective in preventing hospitalisation for infants whose mothers were vaccinated more than 14 days before delivery.
UKHSA has also today published the latest vaccine uptake figures for both RSV programmes, including the:
- older adults programme: overall coverage as of 30 June 2025 in the catch-up cohort (adults aged 75 to 79) reached 62.9%, up from the 60.3% reported in March
- maternal programme: of the 36,657 women reported as having given birth in March 2025, 20,051 (54.7%) had received an RSV vaccine
- maternal coverage varied by ethnic group with the highest coverage reported among the Chinese ethnic group (73.3%) and lowest among Black and Black British Caribbean (26.4%)